Encorafenib — a new agent for advanced-stage disease
Sign Up to like & getrecommendations! Published in 2018 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/s41571-018-0019-x
Abstract: Anti-angiogenic therapy, predominantly with the anti-VEGF antibody bevacizumab, has not been shown to improve the survival of patients with breast cancer. 70% of patients with this disease are overweight or obese; now, data from 99… read more here.
Keywords: agent advanced; new agent; encorafenib new; stage disease ... See more keywords